Related Experiment Video

Updated: Aug 3, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

947

Ocular side effects of Trametinib and Dabrafenib: a case report

Bilge Tarım1, Meltem Kılıç2

  • 1Department of Ophthalmology, University of Health Sciences, Ankara Bilkent City Hospital, Ankara, Turkey. bilge_basciftci@hotmail.com.

Journal of Ophthalmic Inflammation and Infection
|April 12, 2023
PubMed

Insights

This study reports a case of vision loss in a patient with non-small cell lung carcinoma treated with Dabrafenib-Trametinib. Prompt corticosteroid treatment successfully restored vision and resolved ocular complications.

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • Targeted therapy with Dabrafenib-Trametinib is used for advanced non-small cell lung carcinoma.
  • Ocular side effects can occur with targeted cancer therapies, impacting patient quality of life.

Purpose of the Study:

  • To report a case of bilateral decreased visual acuity in a patient undergoing Dabrafenib-Trametinib treatment.
  • To describe the ocular findings and management of this adverse event.

Main Methods:

  • Ophthalmic examinations including slit lamp biomicroscopy, fundoscopy, optical coherence tomography, and fundus fluorescein angiography were performed.
  • Treatment involved discontinuation of Dabrafenib-Trametinib and initiation of systemic and topical corticosteroids and cycloplegics.

Main Results:

  • The patient presented with bilateral posterior synechiae, granulomatous keratic precipitates, anterior chamber cells, cystoid macular edema, and subretinal fluid.
  • Following treatment, best corrected visual acuity improved significantly, and ocular findings completely regressed.

Conclusions:

  • Dabrafenib-Trametinib can cause significant ocular inflammatory side effects.
  • Early diagnosis and aggressive corticosteroid treatment are crucial for managing these visual disturbances and achieving recovery.
Keywords:
Cystoid macular edemaDabrafenibSerous retinal detachmentTrametinibUveitis

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development06:46

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

1.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
227
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
368